View Older Stories View More Recent Stories

Oct 14, 2020 08:00AM Merck Issues 2019/2020 Corporate Responsibility Report
Oct 8, 2020 08:30AM MilliporeSigma Celebrates Topping-Out Ceremony for New Membrane Production Plant
Oct 8, 2020 06:50AM Merck (MRK) Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
Oct 8, 2020 06:45AM Merck Announces Week 96 Data from Phase 2b Study Evaluating Islatravir in Combination With Doravirine in Adults With HIV-1 Infection
Oct 6, 2020 01:00PM MilliporeSigma Inaugurates New, Upgraded Onsite Industrial Water Treatment Plant
Oct 2, 2020 08:06AM Merck (MRK) Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Oct 2, 2020 08:00AM Merck Announces Retirement of Dr. Roger M. Perlmutter; Dr. Dean Y. Li Appointed as President, Merck Research Laboratories
Oct 1, 2020 06:45AM Merck to Present New Data from the Company’s Diverse HIV Portfolio and Pipeline at HIV Glasgow 2020
Oct 1, 2020 06:30AM Merck to Hold Third-Quarter 2020 Sales and Earnings Conference Call on October 27
Sep 28, 2020 06:45AM Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day
Sep 21, 2020 12:32PM Merck's (MRK) KEYTRUDA Plus Chemo Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
Sep 21, 2020 12:30PM Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Locally Advanced or Metastatic Esophageal Cancer
Sep 21, 2020 08:33AM Merck (MRK) Reports First-Line Treatment with KEYTRUDA (pembrolizumab) Doubled 5-Yr Survival Rate (31.9%) vs. Chemotherapy (16.3%) in Certain Patients w/ Metastatic NSCLC & PD-LI Turmors
Sep 21, 2020 08:25AM First-Line Treatment With Merck’s KEYTRUDA® (pembrolizumab) Doubled Five-Year Survival Rate (31.9%) Versus Chemotherapy (16.3%) in Certain Patients With Metastatic Non-Small Cell Lung Cancer Whose
Sep 21, 2020 06:47AM AstraZeneca (AZN) and Merck (MRK) Announce LYNPARZA Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 mCRPC
Sep 21, 2020 06:45AM LYNPARZA® (olaparib) Recommended for Approval in EU by CHMP as First-Line Maintenance Treatment with Bevacizumab for HRD-Positive Advanced Ovarian Cancer
Sep 21, 2020 06:45AM LYNPARZA® (olaparib) Receives Positive Opinion from EU CHMP for Treatment of BRCA1/2 Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sep 20, 2020 12:30PM LYNPARZA Reduced Risk of Death by 31% vs. Enzalutamide or Abiraterone for Men with BRCA1/2 or ATM-Mutated Metastatic Castration Resistant Prostate Cancer Who Progressed Following Enzalutamide or Abira
Sep 20, 2020 12:30PM LYNPARZA® (olaparib) Reduced the Risk of Death by 31% in BRCA1/2 or ATM-mutated Metastatic Castration-Resistant Prostate Cancer in Phase III Profound Trial
Sep 20, 2020 10:20AM Merck Presents Promising New Data for Three Investigational Medicines From Diverse and Expansive Oncology Pipeline at ESMO Virtual Congress 2020
Sep 20, 2020 08:25AM Merck and Eisai Present First-Time Data From Two Studies Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Seven Different Tumor Types at ESMO Virtual Congress 2020
Sep 19, 2020 10:20AM Merck’s KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Sep 18, 2020 06:46AM AstraZeneca (AZN), Merck (MRK) Report LYNPARZA Improved Median PFS to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 18, 2020 06:45AM LYNPARZA® (olaparib) Improved Median Progression-Free Survival to Over Four and a Half Years Compared to 13.8 Months with Placebo for Patients with BRCA-Mutated Advanced Ovarian Cancer
Sep 18, 2020 06:02AM Pfizer (PFE), Merck (MRK) Biopharmaceutical Business, EMD Serono, Reports Publication of BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results
Sep 18, 2020 03:00AM BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine
Sep 16, 2020 06:45AM Merck to Hold Investor Briefing Following ESMO Virtual Congress 2020
Sep 15, 2020 06:45AM Merck to Present at the 2020 Cantor Fitzgerald Virtual Global Healthcare Conference
Sep 14, 2020 06:45AM Seattle Genetics (SGEN) and Merck (MRK) Announce Two Strategic Oncology Collaborations; Merck to Invest $1B
Sep 14, 2020 06:45AM Seattle Genetics and Merck Announce Two Strategic Oncology Collaborations
Sep 10, 2020 06:45AM Merck to Present at the Morgan Stanley 18th Annual Virtual Global Healthcare Conference
Sep 9, 2020 09:00AM MilliporeSigma Announces $65 Million Antibody-Drug Conjugate Manufacturing Expansion
Sep 9, 2020 09:00AM /C O R R E C T I O N -- MilliporeSigma/
Sep 9, 2020 06:46AM Merck (MRK) Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Sep 9, 2020 06:45AM Merck Announces Positive Topline Results from Two Phase 3 Adult Studies Evaluating V114, Merck’s Investigational 15-valent Pneumococcal Conjugate Vaccine, Including Pivotal Trial
Sep 8, 2020 06:48AM Merck's (MRK) Gefapixant Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
Sep 8, 2020 06:45AM Merck’s Gefapixant (45 mg Twice Daily) Significantly Decreased Cough Frequency Compared to Placebo at Week 12 and 24 in Patients with Refractory or Unexplained Chronic Cough
Sep 8, 2020 06:31AM Vaccine makers announce pledge, outlining united commitment to uphold integrity of scientific process
Sep 8, 2020 06:31AM Biopharma Leaders Unite to Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite To Stand With Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 8, 2020 06:30AM Biopharma Leaders Unite to Stand with Science
Sep 4, 2020 06:45AM Merck to Present at the Citi 15th Annual BioPharma Virtual Conference
Sep 2, 2020 06:46AM Merck (MRK) Says New Scientific Data at the ESMO Virtual Congress 2020 Reflect its Commitment to Advancing Cancer Research and Care
Sep 2, 2020 06:45AM New Scientific Data at the ESMO Virtual Congress 2020 Reflect Merck’s Commitment to Advancing Cancer Research and Care
Aug 24, 2020 06:45AM Merck's (MRK) KEYTRUDA Receives Two New Approvals in Japan
Aug 24, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan
Aug 19, 2020 06:58AM Merck's (MRK) KEYTRUDA in Combination With Chemotherapy Significantly Improved OS and PFS Compared With Chemotherapy in Locally Advanced or First-Line Metastatic Esophageal Cancer
Aug 19, 2020 06:45AM Merck’s KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy Significantly Improved Overall Survival and Progression-Free Survival Compared With Chemotherapy in Locally Advanced or First-Line
View More Recent Stories View Older Stories